Delivery Order SPE2DR25D3111-SPE2DR26FF3WY

The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,476.11 to AmerisourceBergen Drug Corp for Trelegy Ellipta 200-62.5-25, a combination inhalation powder used to treat chronic obstructive pulmonary disease. The award was issued on January 13, 2026, with an ultimate completion date of January 14, 2026, and utilized firm fixed-price pricing with no set-aside designation. The place of performance is listed as Conshohocken, Pennsylvania, which serves as AmerisourceBergen's corporate headquarters. This delivery order is a child contract executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a comprehensive pharmaceutical supply vehicle valued at $999,999,999.00 through December 2026 that enables the company to deliver pharmaceutical products and medical supplies globally to support military healthcare programs.

AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc., is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly for military and veteran healthcare systems. The company's federal contract portfolio demonstrates extensive capability in supplying brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains. The competitively awarded delivery orders under the DLA IDC vehicle reflect AmerisourceBergen's ability to fulfill diverse federal medical supply requirements with pricing flexibility, ranging from minimal orders to substantial transactions exceeding $45,000, serving customers including the Defense Health Agency and U.S. Coast Guard.